Australia's largest stock trading and investment forum Australia's #1 stock forum

CDX

0.00%

6.0¢ cardiex limited

I like the report but confusing when in two different parts of...

First 162 Last

Share
Profile

Follow
TraderP

377 Posts.

112

03/06/22

09:36

Post #: 61795861
Share

Originally posted by Bewlidered1976 ↑

CardieX has gets hearts racing after independent equities research shop MST Access placed a $1.50 valuation on the Australian cardiovascular medtech.

https://unauthorised investment advice/health/cardiex-gets-hearts-racing-as-mst-access-reaffirms-value-at-5x-current-share-price/?utm_medium=email&utm_campaign=*%20Morning%20Newsletter-06-02-2022&utm_content=httpsstockheadcomauhealthcardiexgetsheartsracingasmstaccessreaffirmsvalueat5xcurrentshareprice&utm_medium=email&utm_campaign=Morning%20email%20Friday%20June%203&utm_content=Morning%20email%20Friday%20June%203+CID_495cbffc7c2d9b2ee236d321304ebc56&utm_source=Campaign%20Monitor&utm_term=CardieX%20gets%20hearts%20racing%20as%20MST%20Access%20reaffirms%20value%20at%205x%20current%20share%20price
CardieX has gots hearts racing after independent equities research shop MST Access placed a $1.50 valuation on the Australian cardiovascular medtech.
The price equates to an overall market cap of about $165 million versus $32 million currently, as the company is currently trading just below 30c a share on market.
MST is the second leading analyst to put a buy on CardieX in the last six months. In December, with a “spec buy” recommendation and target price of 16 cents. This was on a pre-consolidation basis equating to a target price of $1.60.
Blue Ocean highlighted “early-stage growth potential and the impending nature of the FDA clearance process for the new product suite” which MST Analyst Chris Kallos also notes, flagging that the US FDA’s recent classification of the CONNEQT App as a Medical Device Data System paved the way for the launch of several consumer-facing products over the next six months.
“The app will link all CONNEQT products in a new digital ecosystem based on devices using ATCOR’s SphygmoCor® technology,” he says.

Commercialisation booster

CardieX last year pivoted into the consumer health space and is working on commercialising a range of wearable, consumer health apps and home health devices .
The company is booking more revenues following a 5% quarter-over-quarter increase in cash receipts to roughly $1.1 million at the end of the March quarter. This boosted CardieX’s cash balance to $3.9 million as of March 31, 2022.
Kallos also noted that product development and operating costs were down $320,000 primarily due to prepaid inventory costs for new products in the prior quarter.
CardieX subsidiary ATCOR Medical’s split into two distinct companies – ATCOR and CONNEQT – last year was part of the company’s move to .
In March this year – a world-first consumer smartwatch incorporating ATCOR’s FDA-cleared SphygmoCor® heart-health technology.

Users can monitor their own heart

“This is the first commercial implementation of ATCOR’s heart monitoring technology in a wearable device,” Kallos says.
This coupled with continued advancement towards securing FDA clearance for the CONNEQT Pulse and the CONNEQT Band products in the next financial year and a new clinical trial services agreement with Andwin Scientific has prompted MST Access to reaffirm its valuation.
“We retain our fair value estimate for CardieX at $1.50 per share based on shares on issue of 109.9m (following the 10 for 1 consolidation),” Kallos says in the just released research note.
“This represents a significant premium to the current share price of $0.28 per share.”
The CONNEQT Pulse is anticipated to be the world’s first consumer vital signs monitor to include central blood pressure and other advanced arterial health biometrics, while the CONNEQT Band is a new wearable device focused on arterial health and incorporating similar biometric parameters as the Pulse.
Kallos said the launch of both products should support integration of all products within a digital ecosystem.
This article was developed in collaboration with CardieX, a * advertiser at the time of publishing
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Expand

I like the report but confusing when in two different parts of the research it has 2 different anticipated submission dates.

CardieX remains on track to submit for FDA clearance of
the CONNEQT Pulse and the CONNEQT Band in 2QCY22
and 4QCY22 respectively.
CardieX has completed all of its requirements for US FDA submission of the Pulse device, expected in the 3QCY22.

CDX Price at posting: 28.0¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

SKS

SKS secures $20M for extension works on Melbourne data centre

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

EBR

EBR Systems' heart pacing device on-target to reach the US market

BOE

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s

There are more pages in this discussion • 42 more messages in this thread...

First 162 Last

Add CDX (ASX) to my watchlist

(20min delay)
Last 6.0¢		Change 0.000(0.00%)		Mkt cap ! $17.65M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
2	43455	5.4¢

Sellers (Offers)

Price($)	Vol.	No.
6.1¢	33080	1

View Market Depth

No.	Vol.	Price($)
2	43455	0.054
2	22650	0.053
2	196502	0.052
2	105000	0.051
3	137000	0.050

Price($)	Vol.	No.
0.061	33080	1
0.062	83300	1
0.063	130000	1
0.064	130000	1
0.066	20933	1

Last trade - 16.12pm 04/09/2024 (20 minute delay)

CDX (ASX) Chart

Day chart unavailable

I like the report but confusing when in two different parts of...

SKS secures $20M for extension works on Melbourne data centre

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

EBR Systems' heart pacing device on-target to reach the US market

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I like the report but confusing when in two different parts of...

Top Stories

SKS secures $20M for extension works on Melbourne data centre

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

EBR Systems' heart pacing device on-target to reach the US market

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News